{"id":7151,"date":"2022-10-06T16:09:11","date_gmt":"2022-10-06T14:09:11","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=7151"},"modified":"2022-10-07T16:13:36","modified_gmt":"2022-10-07T14:13:36","slug":"aifa-business-plan-2022","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/aifa-business-plan-2022\/","title":{"rendered":"AIFA Business Plan 2022"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"7151\" class=\"elementor elementor-7151\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ca50063 e-flex e-con-boxed e-con e-parent\" data-id=\"ca50063\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-77d0ad9 elementor-widget elementor-widget-text-editor\" data-id=\"77d0ad9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>The\u00a0<strong>28 September 2022<\/strong> the State-Regions Conference postponed its opinion (item 7) for the AIFA Business Plan 2022.\u00a0<\/p><p>The plan identifies 3 corporate missions:<\/p><ol><li><strong>guarantee<\/strong> the unity of the <strong>activities<\/strong> in the field of pharmaceuticals;<\/li><li><strong>monitor<\/strong> consumption and <strong>expenditure<\/strong> pharmaceuticals;<\/li><li><strong>favour<\/strong> in Italy <strong>information<\/strong> independent and <strong>reinvestments<\/strong> at <strong>R&amp;D<\/strong>.<\/li><\/ol><p>Linked to each mission are one or more guidelines (8 in total), each of which defines specific objectives measurable through ad hoc indicators and with targets to be achieved.<\/p><p>The AIFA 2022 activity plan was supplemented with the\u00a0<strong>actions for governance <\/strong><strong>pharmaceuticals<\/strong> whose objective is to assess the context and the actions that AIFA puts in place to ensure the sustainability of pharmaceutical expenditure.<\/p><p>Among them are:<\/p><ul><li><strong>Renegotiations<\/strong> and contracts<\/li><li><strong>AIFA Notes<\/strong> - for optimal uses of drugs (prescriptive appropriateness)<\/li><li>Strengthening of <strong>transparency lists<\/strong><\/li><li><strong>Law 648\/96<\/strong> and expenditure impact (+Annex 1. Procedure for 'inclusion of drugs in the ista of L. 648\/1936 after the entry into force of the Ministerial Decree of 2 August 2019 and the AIFA price negotiation guideline.<\/li><li>Simplification and <strong>parallel imports<\/strong><\/li><\/ul><p>They are <strong>measures that AIFA uses to manage\/reduce pharmaceutical expenditure linked to the revision of the NFP and the realignment of prices in the contracted sector<\/strong>.<\/p><p>For further details please read the summary in which we have indicated in green the actions already in place and in red those planned.<\/p><p>\u00a0<\/p><p><div class=\"_df_book df-lite\" id=\"df_7162\"  _slug=\"piano-di-attivita-aifa-2022\" data-title=\"piano-di-attivita-aifa-2022\" wpoptions=\"true\" thumbtype=\"\" ><\/div><script class=\"df-shortcode-script\" nowprocket type=\"application\/javascript\">window.option_df_7162 = {\"outline\":[],\"backgroundColor\":\"eeeeee\",\"duration\":\"0\",\"autoEnableOutline\":\"false\",\"autoEnableThumbnail\":\"false\",\"overwritePDFOutline\":\"false\",\"enableDownload\":\"true\",\"direction\":\"1\",\"pageSize\":\"0\",\"pageMode\":\"1\",\"soundEnable\":\"false\",\"autoPlay\":\"false\",\"source\":\"https:\\\/\\\/pharmavalue.it\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/PIANO-ATTIVITA-AIFA-2022_SD3.pdf\",\"wpOptions\":\"true\"}; if(window.DFLIP && window.DFLIP.parseBooks){window.DFLIP.parseBooks();}<\/script><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>ll\u00a028 settembre 2022 la Conferenza Stato Regioni ha rinviato il parere (punto 7) per\u00a0il\u00a0Piano attivit\u00e0 di AIFA 2022. Il\u00a0piano individua 3 mission aziendali: garantire l\u2019unitariet\u00e0 delle attivit\u00e0 in materia di farmaceutica; monitorare il consumo e la spesa farmaceutica; favorire in Italia l\u2019informazione indipendente e di rinvestimenti in R&amp;S. Ad ogni mission sono collegate una o [&hellip;]<\/p>\n","protected":false},"author":314,"featured_media":7153,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[38],"tags":[],"class_list":["post-7151","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analisi-di-scenario"],"_links":{"self":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/7151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/users\/314"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/comments?post=7151"}],"version-history":[{"count":0,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/7151\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media\/7153"}],"wp:attachment":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media?parent=7151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/categories?post=7151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/tags?post=7151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}